Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

| More on:
A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Orthocell Ltd (ASX: OCC) shares are catching the eye again on Friday.

In morning trade, the ASX All Ords stock is up 7% to $1.51.

Why is this ASX All Ords stock jumping today?

Investors have been buying the regenerative medicine company's shares following the release of an announcement relating to its flagship Remplir product.

Remplir is a collagen wrap used in nerve repair surgery to assist surgeons to improve outcomes in the repair and regeneration of damaged nerves.

It was recently given the thumbs up by the US Food & Drug Administration, paving the way for the company to start generating revenue in the country.

Orthocell is targeting a large global addressable nerve repair market estimated to be worth in excess of US$3.5 billion.

What is today's news?

According to the release, the company has added a further eight distributors for Remplir, taking the total number of US distributors signed to 12.

Management notes that the signing of distributors has progressed well ahead of expectations with the company previously only targeting 10 distributors in place by 30 June. It feels that the rapid signing of these new distributors is a testament to the quality of Remplir and the distributors' belief in being able to generate strong sales for the product in the US.

Following these new appointments, the ASX All Ords stock's distributor group collectively covers 21 US states. And with these relationships non-exclusive, the company intends to continue signing additional distributors to expand access to the US market.

'Confident'

Commenting on the news, Orthocell's CEO and managing director, Paul Anderson, said:

It's very pleasing to see such rapid progress on the expansion of our US distributor network so soon after receiving US FDA clearance in April. We're well ahead of the targets we had set ourselves and expect that to translate to first US Remplir sales this quarter.

Our US team has been working tirelessly leading up to the product launch and we're confident we have the right strategy to drive market penetration of the US. For us, that means a combination of experienced internal employees complemented by a portfolio of distributors who have active sales channels to reach and engage our customers. We expect to grow our portfolio of distributors too.

Following today's strong gain, this ASX All Ords stock is now up almost 300% since this time last year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Bell Potter names the best ASX healthcare shares to buy in 2026

Healthy returns could be on offer with these shares according to the broker.

Read more »

man cupping ear as if to listen closely, rumour, cochlear
Healthcare Shares

Why is everyone talking about Telix shares this week?

Let's see why this biotech stock has been on the move this week.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX stock is going parabolic, and I think it's still a buy

4DMedical shares are up nearly 500% in 2025, but improving revenue visibility suggests the growth story may not be over.

Read more »

ecommerce asx shares represented by santa doing online shopping on laptop
Healthcare Shares

Looking for ideas before Christmas? These 2 ASX shares stand out to me

Two ASX shares at opposite ends of the market are catching my attention as the year draws to a close.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

A male ASX investor sits cross-legged with a laptop computer in his lap with a slightly crazed, happy, excited look on his face while next to him a graphic of a rocket shoots upwards with graphics of stars scattered around it
Healthcare Shares

Up 10x since July, could this hot ASX stock be the next Droneshield?

Investors chase asymmetric upside and 4DMedical is one of the ASX's hottest stocks right now.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Is Medibank stock a buy for its 5.5% dividend yield?

This business is providing investors with very healthy dividends.

Read more »